论文部分内容阅读
目的:观察血府逐瘀汤联合干扰素治疗慢性乙型肝炎所致肝纤维化的治疗效果。方法:选取180例慢性乙型肝炎所致肝纤维化患者作为研究对象,并随机分为观察组和对照组各90例。对照组采用干扰素进行治疗,观察组采用血府逐瘀汤联合干扰素进行治疗。观察比较2组患者的治疗效果及不良反应情况。结果:治疗后,2组层粘连蛋白(LN)、透明质酸(HA)、Ⅲ型前胶原蛋白(PCⅢ)水平以及门静脉主干内径、门静脉平均血流量、门静脉平均血流速度均较治疗前下降(P<0.01);观察组LN、HA、PCⅢ水平以及门静脉主干内径、血流量均低于对照组(P<0.01),门静脉平均血流速度高于对照组(P<0.01)。观察组不良反应发生率为8.89%,略低于对照组的11.11%,差异无统计学意义(P>0.05)。结论:血府逐瘀汤联合干扰素可以有效控制患者的肝纤维化进展情况,改善患者的门静脉血流状况,同时不良反应发生率较低,值得在临床推广应用。
Objective: To observe the therapeutic effect of Xuefu Zhuyu Decoction combined with interferon on liver fibrosis induced by chronic hepatitis B Methods: 180 patients with liver fibrosis due to chronic hepatitis B were selected as research object and randomly divided into observation group and control group with 90 cases each. The control group was treated with interferon. The observation group was treated with Xuefu Zhuyu decoction combined with interferon. Observed and compared two groups of patients with treatment and adverse reactions. Results: After treatment, the levels of laminin (LN), hyaluronic acid (HA), procollagen Ⅲ (Ⅲ) and the main trunk diameter of portal vein, mean portal vein blood flow and mean portal vein blood flow decreased compared with those before treatment (P <0.01). The levels of LN, HA and PCⅢ in the observation group, as well as the main trunk diameter and blood flow in the portal vein were lower than those in the control group (P <0.01), and mean portal blood flow velocity was higher than that in the control group (P <0.01). The incidence of adverse reactions in the observation group was 8.89%, slightly lower than that in the control group (11.11%), with no significant difference (P> 0.05). Conclusion: Xuefuzhuyu Decoction combined with interferon can effectively control the progress of liver fibrosis in patients with portal vein blood flow to improve the situation, while the incidence of adverse reactions is low, it is worth in the clinical application.